Health-care companies fell as fears about health insurers offset deal and lawsuit activity.
Novo Nordisk rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims & Hers in an attempt to block any further sales of copycat versions of its weight-loss medications.
Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
February 09, 2026 17:44 ET (22:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.